| Reduced Risk Status: |
|
| IPM Compatibility: |
PER REQUESTOR VERYGOODFIT, NEW FRAC GROUP AND NOT EXPECTED TO BE HARMFUL TO BENEFICIALS.
|
| Reasons for need: |
POWDERY MILDEW; ROTATIONAL PRODUCT FOR RESISTANCE MANAGEMENT, THIS PRODUCT IS A UNIQUE FRAC GROUP PER CORTEVA PRESENTATION (IR-4 2021)
|
| Requesting State(s): |
FL:Bledsoe, M* ;
|
| PCR Use Pattern: |
GF-4031, 35 -50 G AI/HA, 0.03-0.04 LB AI/A; 20G/L EC; APPLIED FOLIARLY WITH 3 APPLICATIONS AND A 7 DAY RETREATMENT INTERVAL; 0-1 DAY PHI;
|
| EPA Default Residue Trials: |
ANY 4 TRIALS
|
| IR-4 Residue Trial Plan: |
Any 4 trials (large & small); NAFTA ANY 4 (Possible 4 declines dependent on PHI)
|
| Residue Protocol Use Pattern: |
CANADA SERVING AS SPONSOR AND STUDY DIRECTOR; USE THE GF-4031 FUNGICIDE PRODUCT (1.67 LB AI/GAL); MAKE 2 FOLIAR DIRECTED APPLIC OF 0.0669 LB AI/A, IN AT LEAST 30 GPA, 7-DAY INTERVAL, 1-DAY PHI
|
| Efficacy/Crop Safety (E/CS) Data Required: |
|
| E/CS Research Comments: |
Corteva indicated that efficacy data from Canada is acceptable for the USA. Canada plans 4 efficacy trials so Corteva will not need any 2024 trials in the USA:3/24/sb;
|
| Label Use Pattern Submitted To EPA: |
|
| EPA PIF Status: |
Blue 08/22; Blue: 08/23
|
| EPA Status: |
|
| EPA PRIA Date: |
|
| MRID: |
|
| Comments: |
Canadian Study# AAFC24-006R:01/24/sb; Category of "Researchable, Residue & E/CS data needed" has been updated to "Complete with On-Going Trials":03/24/sb; in Nov 2023, Corteva advised that efficacy data from Canada is acceptable for the USA. Canada plans 4 efficacy trials so Corteva will not need any 2024 trials in the USA:3/24/sb;
|
| International Status: |
|
| Archive Location: |
|
| QA Archive: |
|